Effect of Propolis on Tamoxifen- Induced Nonalcoholic Fatty Liver

The Effect of Iranian Propolis on Tamoxifen- Induced Nonalcoholic Fatty Liver in Breast Cancer Patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161017030341N1

Enrollment

Registered

2025-04-23

Start date

2025-02-19

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tamoxifen- Induced Nonalcoholic Fatty Liver in Breast Cancer Patients. Other diseases of liver

Interventions

Intervention 1: Propolis capsules are taken as 500 mg (made by Shahdineh Golha Company) twice daily for 3 months. Everyone is advised to maintain a healthy diet and exercise for 30 minutes daily. Inte

Eligibility

Sex/Gender

Female

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Women over 20 years old Bbreast cancer with positive estrogen receptor Treated with tamoxifen Elevated liver enzyme Fatty liver was confirmed by Sonography.

Exclusion criteria

Exclusion criteria: History of alcohol consumption of more than 70 cc per week Viral or autoimmune hepatitis diabetes Taking drugs affecting liver enzymes in the last 2 months (statins, glitazones, chlorpromazine, OCP, anabolic steroids, thionamides) Consumption of nutritional supplements, vitamins and minerals History of allergic reactions to bee products

Design outcomes

Primary

Measure	Time frame
Change in fatty liver grade. Timepoint: At the outset of the study (before the intervention), The study concluded 3 months after the intervention. Method of measurement: Sonography.	—

Secondary

Measure	Time frame
Changes in AST levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Changes in ALT levels. Timepoint: both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Changes in ALP levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Changes in Total Bilirubin levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Changes in Serum albumin levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Changes in GGT levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Changes in TG levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Change in cholesterol levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Change in HDL levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Change in LDL levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.	—

Measure

Time frame

Changes in AST levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Changes in ALT levels. Timepoint: both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Changes in ALP levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Changes in Total Bilirubin levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Changes in Serum albumin levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Changes in GGT levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Changes in TG levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Change in cholesterol levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Change in HDL levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.;Change in LDL levels. Timepoint: Both before the intervention at the start of the trial and following it. Method of measurement: Laboratory kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHemn Baooshi

Sanandaj University of Medical Sciences

hemnbaooshi@yahoo.com+98 87 3328 6112

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026